Autobio Diagnostics Co., Ltd. (603658.SS)
CNY 38.71
(-0.74%)
CNY 38.71
(-0.74%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.03 Billion CNY | 683.29% |
| 2022 | 132.54 Million CNY | -43.86% |
| 2021 | 236.07 Million CNY | 17.96% |
| 2020 | 200.13 Million CNY | -74.82% |
| 2019 | 794.88 Million CNY | 720.41% |
| 2018 | 96.88 Million CNY | 148.43% |
| 2017 | 39 Million CNY | 0.0% |
| 2016 | - CNY | -100.0% |
| 2015 | 95.7 Million CNY | 186.92% |
| 2014 | 33.35 Million CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 934 Million CNY | -8.61% |
| 2024 Q1 | 1.02 Billion CNY | -1.56% |
| 2024 Q3 | 253.7 Million CNY | -70.33% |
| 2023 Q3 | 687.9 Million CNY | 19.27% |
| 2023 Q4 | 1.03 Billion CNY | 50.92% |
| 2023 FY | 1.03 Billion CNY | 683.29% |
| 2023 Q1 | 382.94 Million CNY | 188.92% |
| 2023 Q2 | 576.78 Million CNY | 50.62% |
| 2022 Q4 | 132.54 Million CNY | -43.34% |
| 2022 Q3 | 233.91 Million CNY | -2.49% |
| 2022 Q2 | 239.9 Million CNY | 1.2% |
| 2022 FY | 132.54 Million CNY | -43.86% |
| 2022 Q1 | 237.05 Million CNY | 0.42% |
| 2021 Q1 | 216.85 Million CNY | 8.35% |
| 2021 Q3 | 142.62 Million CNY | -25.29% |
| 2021 Q4 | 236.07 Million CNY | 65.52% |
| 2021 FY | 236.07 Million CNY | 17.96% |
| 2021 Q2 | 190.92 Million CNY | -11.96% |
| 2020 Q2 | 219.41 Million CNY | 338.84% |
| 2020 Q3 | 219.47 Million CNY | 0.03% |
| 2020 FY | 200.13 Million CNY | -74.82% |
| 2020 Q4 | 200.13 Million CNY | -8.81% |
| 2020 Q1 | 50 Million CNY | -93.71% |
| 2019 Q4 | 794.88 Million CNY | -3.81% |
| 2019 FY | 794.88 Million CNY | 720.41% |
| 2019 Q3 | 826.37 Million CNY | 111.37% |
| 2019 Q2 | 390.95 Million CNY | 130.76% |
| 2019 Q1 | 169.42 Million CNY | 74.86% |
| 2018 Q2 | 100.95 Million CNY | 46.31% |
| 2018 Q4 | 96.88 Million CNY | -0.3% |
| 2018 FY | 96.88 Million CNY | 148.43% |
| 2018 Q3 | 97.17 Million CNY | -3.74% |
| 2018 Q1 | 69 Million CNY | 76.92% |
| 2017 Q2 | 8.94 Million CNY | 0.0% |
| 2017 Q1 | - CNY | 0.0% |
| 2017 Q3 | 37.8 Million CNY | 322.39% |
| 2017 Q4 | 39 Million CNY | 3.17% |
| 2017 FY | 39 Million CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q3 | - CNY | -100.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 FY | - CNY | -100.0% |
| 2016 Q2 | 97.04 Million CNY | 0.0% |
| 2015 Q1 | 79 Million CNY | 0.0% |
| 2015 FY | 95.7 Million CNY | 186.92% |
| 2015 Q4 | 95.7 Million CNY | 0.0% |
| 2015 Q2 | 79 Million CNY | 0.0% |
| 2015 Q3 | - CNY | -100.0% |
| 2014 FY | 33.35 Million CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 6.85 Billion CNY | 84.845% |
| Joinn Laboratories(China)Co.,Ltd. | 85.79 Million CNY | -1110.104% |
| WuXi AppTec Co., Ltd. | 5.75 Billion CNY | 81.963% |
| Thalys Medical Technology Group Inc. | 1.05 Billion CNY | 1.232% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 578.98 Million CNY | -79.314% |
| Chemclin Diagnostics Co., Ltd. | 234.6 Million CNY | -342.523% |